RxDoctor Payments Data

Raul Perez, MD

Family Medicine · Visalia, CANPI 1477509289

Payments from drug & device makers

$580in general payments, 2019–2025

Across 19 payments — averaging $30.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$124
  • Ironwood Pharmaceuticals, Inc$96
  • AstraZeneca$80
  • Novo Nordisk$50
  • Amarin Pharma, Inc.$43
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$580 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$88,924
Medicare patients
322
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$75,354
OzempicSemaglutide29$42,846
TrulicityDulaglutide23$35,356
EliquisApixaban29$22,567
Xultophy 100-3.6Insulin Degludec/Liraglutide12$22,351
LinzessLinaclotide19$19,392
JanuviaSitagliptin Phosphate21$18,866
XareltoRivaroxaban15$14,066
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$13,113
InvokanaCanagliflozin15$10,816
EntrestoSacubitril/Valsartan11$7,271
Breo ElliptaFluticasone/Vilanterol14$5,638
SymbicortBudesonide/Formoterol Fumarate20$5,097
Serevent DiskusSalmeterol Xinafoate12$4,961
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$50$67,17452 claims
PfizerEliquis$16$22,56729 claims
AbbVieLinzess$14$19,39219 claims
GSKBreo Ellipta$15$5,63814 claims
AstraZenecaSymbicort$80$5,09720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →